Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A 15-year-old girl with acute renal failure was found to have class IV systemic lupus erythematosus (SLE) nephritis on renal biopsy. A decision was taken to start her on the routine National Institute of Health protocol of pulsed methyl-prednisolone and monthly intravenous cyclophosphamide (CYC) (0.5–1.0 g/m2 of body surface area). With her post-pubertal status and the possibility of CYC induced gonadal toxicity, the question was raised as to whether she should be put on gonadotropin releasing hormone analogue (GnRH-a) therapy for ovarian protection.
STRUCTURED CLINICAL QUESTION
In young female patients with SLE undergoing CYC therapy [patient], does the use of GnRH-a [intervention], when compared to no intervention [comparison], prevent premature ovarian failure [outcome]?
[Lupus or Systemic lupus erythematosus] AND [cyclophosphamide] AND [gonadal toxicity or premature ovarian failure or fertility] AND [gonadotropin releasing hormone analogue or GnRH or GnRH-a] Limits: English, Human
Cochrane Library: None relevant
Medline: 1950–to date; EMBASE: 1974–to date; CINAHL: 1982–to date via Dialog DataStar
The search was conducted independently by both authors between December 2006 and January …
Competing interests: None.